The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions by Yuxin Liu, Clifton Mo, Monique Hartley-Brown, Shonali Midha, Adam S. Sperling, Giada Bianchi, Omar Nadeem, Betsy O’Donnell, Jacob Laubach, Paul G. Richardson

Get full text

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects by Alberto L. Horenstein, Angelo C. Faini, Angelo C. Faini, Fabio Morandi, Erika Ortolan, Paola Storti, Nicola Giuliani, Nicola Giuliani, Paul G. Richardson, Fabio Malavasi, Fabio Malavasi

Get full text

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm by Charlotte Pawlyn, Fredrik H. Schjesvold, David A. Cairns, L. J. Wei, Faith Davies, Omar Nadeem, Haifaa Abdulhaq, Maria-Victoria Mateos, Jacob Laubach, Katja Weisel, Heinz Ludwig, S. Vincent Rajkumar, Pieter Sonneveld, Graham Jackson, Gareth Morgan, Paul G. Richardson

Get full text

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial by Omar Nadeem, Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody, Jean-Baptiste Alberge, Luca Bertamini, Ankit K. Dutta, Habib El-Khoury, Mark Bustoros, Jacob P. Laubach, Giada Bianchi, Elizabeth O’Donnell, Ting Wu, Junko Tsuji, Kenneth C. Anderson, Gad Getz, Lorenzo Trippa, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Irene M. Ghobrial

Get full text